Qiagen

Qiagen, AstraZeneca collaborate for lung cancer patients

Monday, July 28, 2014 02:53 PM

Qiagen, a Netherlands-based holding company, has announced a collaboration agreement with AstraZeneca for the co-development and commercialization of a liquid biopsy-based companion diagnostic to be paired with IRESSA, AZ's targeted therapy for non-small cell lung cancer (NSCLC).

More... »

WIRB Copernicus Group

Qiagen, Eli Lilly collaborate to co-develop companion diagnostics

Tuesday, June 3, 2014 11:17 AM

Qiagen, a Netherlands-based holding company, is collaborating with Eli Lilly to co-develop universal and modular assay panels for the simultaneous analysis of DNA and RNA biomarkers targeting multiple cellular pathways involved in common cancer types. The agreement includes the development of tests that will be based on Qiagen's multi-modal, multi-analyte Modaplex analysis platform, which can process multiple sample types and biomarkers in a single test.   

More... »


Qiagen, Exosome Diagnostics to develop diagnostics for cancer

Monday, January 13, 2014 11:42 AM

Qiagen, a Netherlands-based holding company, has expanded its strategic partnership with Exosome Diagnostics to develop a first-in-class, non-invasive molecular in-vitro diagnostics for use in diagnosing and monitoring patients.

More... »

Qiagen acquires Ingenuity Systems

Wednesday, May 1, 2013 10:30 AM

Qiagen, a Netherlands-based global provider of sample and assay technologies, has acquired Ingenuity Systems, a Redwood City, Calif.-based provider of software solutions to efficiently and accurately analyze and interpret the biological meaning of genomic data.

More... »

Qiagen acquires AmniSure International

Friday, May 4, 2012 02:59 PM

Netherlands holding company Qiagen has acquired AmniSure International, a privately owned Boston company that markets the AmniSure assay for determining whether a pregnant woman is suffering rupture of fetal membranes (ROM), a condition in which fluid leaks from the amniotic sac prematurely. Financial terms were not disclosed.

More... »

WuXi AppTec Partners with Qiagen to Develop Biomarkers

Tuesday, January 12, 2010 06:11 AM

Chinese contract research organization (CRO) WuXi AppTec has entered into a partnership with Netherlands holding company Qiagen to provide biomarker development, validation and personalized healthcare diagnostics. Neither company provided the financial details of the agreement.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

August 25

Verizon Communications enters clinical trial space with technology, network, and cloud and data services

Sponsors look to the power of genomic profiling to screen, enroll patients in trials for targeted therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs